

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 15864

Title: Treatment of chronic hepatitis C in liver transplant candidates and recipients: where do we stand?

Reviewer's code: 01588404

Reviewer's country: India

Science editor: Xue-Mei Gong

Date sent for review: 2014-12-13 20:59

Date reviewed: 2014-12-31 19:38

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is a well written review describing the recent advances in an evolving scenario. Minor comments Table 7 needs to be reformatted

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 15864

Title: Treatment of chronic hepatitis C in liver transplant candidates and recipients: where do we stand?

Reviewer's code: 02860897

Reviewer's country: Japan

Science editor: Xue-Mei Gong

Date sent for review: 2014-12-13 20:59

Date reviewed: 2014-12-21 09:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Transplant-related HCV infection has been intractable state that frequently induces graft loss. Efficacy of treatment regimens containing IFN depends on host immune responses; therefore, the rate of successful treatment is very low in such an immunosuppressed state. Now paradigm shift of the HCV treatment is ongoing and newly developed antiviral agent Sovaldi is very effective in any clinical setting including transplant related HCV infection. This review is well written, timely and concise. I have following questions. 1. P5 L10 The word of "viral cycle" is inarticulate. Change to viral life cycle or viral replication. 2. P6 L13 Dankliza is incorrect. Change to Daklinza. 3. P10 L7 I think four weeks is too short. Is it correct? I think 8 or 12 weeks. 4. P12 L15 Please describe the new DAAs which is contraindication for coadministration of CsA. 5. P14 Please summarize the drug-drug interaction in new Table. 6. P16 Cost of new DAAs are serious social burden. Please add the future direction of anti-HCV treatment in the section of conclusion. If possible immune therapy or therapeutic vaccine.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 15864

Title: Treatment of chronic hepatitis C in liver transplant candidates and recipients: where do we stand?

Reviewer's code: 00742516

Reviewer's country: China

Science editor: Xue-Mei Gong

Date sent for review: 2014-12-13 20:59

Date reviewed: 2014-12-22 13:20

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> [Y] Accept
<input checked="" type="checkbox"/> [Y] Grade B: Very good	<input checked="" type="checkbox"/> [Y] Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> [Y] No	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> [Y] No	

COMMENTS TO AUTHORS

This review provided us the current knowledge about Treatment of chronic hepatitis C in liver transplant candidates and recipients. It is well-written, although some minor errors need to be modified. The following are some examples. Abstract: "various combinations of second generations DAAs associated with" "second generation DAAs", "Are associated with" "new antivirals high cost" new antivirals' high cost core tips: "led to excellent" Excellent is adjective. HCV positive liver transplant candidates: Peg-IFN-based regimens have also been related to poor tolerability and many side effects [3, 5] such as anemia, infections and neuropsychiatric disorders [21] Ref. 21 is not about the side effects of INF. Is infection one of the side effects of IFN? Table 2: What does the asterisk mean? What is CNI? The fonts of the table titles are not consistent.